Hormone replacement therapy and breast cancer: Estimate of risk

British Medical Journal

Volumn 331, Issue 7512, 2005, Pages 347-349

  Coombs, Nathan J ^a   Taylor, Richard ^b   Wilcken, Nicholas ^a   Boyages, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE;

AGE; BREAST CANCER; CALCULATION; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG FORMULATION; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HEALTH EDUCATION; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 23444436900     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.331.7512.347     Document Type: Review

References (27)

1. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
2. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
3. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;60:942-4.
4. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 2003;289:3243-53.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59.
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
7. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
8. Anderson GL, Limacher M, Assaf AR, Bassford T. The effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The women's health initiative randomized controlled trial. JAMA 2004;291:1701-12.
9. Shapiro S. The million women study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3-7.
10. Coombs NJ, Boyages J. Changes in HRT prescriptions dispensed in Australia since 1992. Aust Fam Phys (in press).
11. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy use over a decade in an Australian population. Climacteric 2002;5:351-6.
12. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-8.
13. Taylor R, Boyages J. Absolute risk of breast cancer for Australian women with a family history. Aust NZ J Surg 2000;70:725-31.
14. Taylor R. Risks of premature death from smoking in 15-year-old Australians. Aust J Public Health 1993;17:358-64.
15. Taylor R. Estimating risk for tobacco-induced mortality from readily available information. Tobacco Control 1993;2:18-23.
16. Day NE. Cumulative rate and cumulative risk. Cancer incidence in five continents. IARC Sci Publ 1992;120:862-4.
17. Cornfield J. The estimation of the probability of developing a disease in the presence of competing risks. Am J Public Health 1957;47:601-7.
18. Taylor R, Boyages J. Estimating risk of breast cancer from population incidence affected by widespread mammographic screening. J Med Screening 2001;8:73-6.
19. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford: Blackwell Science, 1994.
20. MacLennan AH, Taylor AW, Wilson DH. Changes in use of hormone replacement therapy in South Australia. Med J Aust 1995;162:420-2.
21. MacLennan AH, MacLennan A, Wilson D. The prevalence of oestrogen replacement therapy in south Australia. Maturitas 1993;16:175-83.
22. Isaacs AJ, Britton AR, McPherson K. Utilisation of hormone replacement therapy by women doctors. BMJ 1995;311:1399-1401.
23. McNagny SE, Wenger NK, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Int Med 1997;127:1093-6.
24. Andersson K, Mattsson L-A, Milsom I. Use of hormone replacement therapy. Lancet 1996;348:1521.
25. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J, Bergman U. Low use of long-term hormone replacement therapy in Denmark. Br J Clin Pharmacol 1999;47:323-8.
26. Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet 1997;350:1277-83.
27. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997;145:536-45.